Literature DB >> 3764809

Heparin fractions with high and low affinities to antithrombin III are cleared at different rates.

C Caranobe, M Petitou, D Dupouy, A M Gabaig, P Sié, M R Buchanan, B Boneu.   

Abstract

The clearance characteristics of standard heparin (SH) and its fractions with high and low affinity to antithrombin III (HAH and LAH respectively) were studied by injecting 125I-labelled SH, HAH and LAH intravenously into the rabbits in increasing doses. Serial blood samples were then collected from an indwelling cannula for measurement of clearance, based both on radioactivity and anticoagulant activity. For equivalent weights injected, the radioactivity of HAH was cleared more slowly from the circulation than that of either SH or LAH. The radioactivity of SH, in turn, was cleared more slowly than that of LAH. The clearance of HAH, measured both by radioactivity and by anticoagulant activity were similar, whereas the clearance of the radioactivity of SH was more rapid than its anticoagulant activity (i.e. anti-factor Xa activity). These observations suggest that the radioactivity clearance curves of SH reflect a "net" estimation of the more complex clearance curves of the different heparin moieties whereas the anticoagulant clearance curves of SH reflects the clearance of the anticoagulant activity of a specific heparin fraction, in this case, the clearance of the anti-factor Xa activity of HAH. These differences suggest that the HAH:LAH ratio is, at any given time, greater in vivo than the same ratio measured in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3764809     DOI: 10.1016/0049-3848(86)90100-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers.

Authors:  J Dawes; M McLaren; C Forbes; J J Belch; D A Lane; B Bray; J McEwen; G Houin; F Gianese
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 2.  Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?

Authors:  Jenneke Leentjens; Mike Peters; Anne C Esselink; Yvo Smulders; Cornelis Kramers
Journal:  Br J Clin Pharmacol       Date:  2017-07-09       Impact factor: 4.335

Review 3.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 4.  Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.

Authors:  Marina Amerali; Marianna Politou
Journal:  Eur J Clin Pharmacol       Date:  2022-07-23       Impact factor: 3.064

Review 5.  Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?

Authors:  Kristian B Johansen; Torben Balchen
Journal:  Exp Hematol Oncol       Date:  2013-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.